Hai-ping Y. Dai

China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

The Regimen of Cladribine, Cytarabine, and Venetoclax (CAV) Induces Apoptosis in Acute Myeloid Leukemia Cells by Enhancing DNA Damage.

The Regimen of Cladribine, Cytarabine, and Venetoclax (CAV) Induces Apoptosis in Acute Myeloid Leukemia Cells by Enhancing DNA Damage.

Journal: Journal of visualized experiments : JoVE

Published: March 23, 2026

Low-Dose Chidamide Maintenance Therapy After Hematopoietic Stem Cell Transplantation for T-Cell Acute Lymphoblastic Leukemia: A Case Series.

Low-Dose Chidamide Maintenance Therapy After Hematopoietic Stem Cell Transplantation for T-Cell Acute Lymphoblastic Leukemia: A Case Series.

Journal: Hematological oncology

Published: March 18, 2026

Prevalence and influencing factors of chronic kidney disease-associated pruritus in patients undergoing maintenance hemodialysis

Prevalence and influencing factors of chronic kidney disease-associated pruritus in patients undergoing maintenance hemodialysis

Journal: Zhonghua yi xue za zhi

Published: March 12, 2026

Coexistence of BCR::ABL1 with IKZF1::ETV6 fusion in an adult patient with acute B-lymphoblastic leukemia.

Coexistence of BCR::ABL1 with IKZF1::ETV6 fusion in an adult patient with acute B-lymphoblastic leukemia.

Journal: Leukemia & lymphoma

Published: February 04, 2026

A Study of Flow Sorting Lymphocyte Subsets to Detect Epstein-Barr Virus Reactivation in Patients with Hematological Malignancies

A Study of Flow Sorting Lymphocyte Subsets to Detect Epstein-Barr Virus Reactivation in Patients with Hematological Malignancies

Journal: Zhongguo shi yan xue ye xue za zhi

Published: November 14, 2025

Venetoclax plus hypomethylating agents versus priming regimen as the first-line therapy for newly diagnosed acute myeloid leukemia with myelodysplasia-related changes: a propensity score-matched analysis.

Venetoclax plus hypomethylating agents versus priming regimen as the first-line therapy for newly diagnosed acute myeloid leukemia with myelodysplasia-related changes: a propensity score-matched analysis.

Journal: Leukemia & lymphoma

Published: October 06, 2025

New selective and allosteric FLT3 inhibitors show efficacy against resistant acute myeloid leukemia cells.

New selective and allosteric FLT3 inhibitors show efficacy against resistant acute myeloid leukemia cells.

Journal: iScience

Published: September 14, 2025

A phase 2 trial of a "sandwich" strategy: Sequential CD22/CD19 chimeric antigen receptor T-cells therapy combined with autologous hematopoietic stem cell transplantation in patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.

A phase 2 trial of a "sandwich" strategy: Sequential CD22/CD19 chimeric antigen receptor T-cells therapy combined with autologous hematopoietic stem cell transplantation in patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.

Journal: Cancer

Published: August 01, 2025

Donor- and patient-derived interleukin 6 knockdown CD19-targeted chimeric antigen receptor T cells exhibit similar efficacy and safety in treating relapsed B-cell acute lymphoblastic leukemia patients after allogeneic hematopoietic stem cell transplantation.

Donor- and patient-derived interleukin 6 knockdown CD19-targeted chimeric antigen receptor T cells exhibit similar efficacy and safety in treating relapsed B-cell acute lymphoblastic leukemia patients after allogeneic hematopoietic stem cell transplantation.

Journal: Cytotherapy

Published: July 31, 2025

IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) for patients with relapsed or refractory acute lymphoblastic leukemia: phase 1 trial.

IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) for patients with relapsed or refractory acute lymphoblastic leukemia: phase 1 trial.

Journal: Blood cancer journal

Published: July 18, 2025

Phase II study of dual epigenetic targeting with chidamide and azacitidine in patients with high-risk acute myeloid leukemia after allo-HSCT.

Phase II study of dual epigenetic targeting with chidamide and azacitidine in patients with high-risk acute myeloid leukemia after allo-HSCT.

Journal: Clinical epigenetics

Published: June 08, 2025

Venetoclax plus azacitidine in relapsed or refractory T-cell acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 trial.

Venetoclax plus azacitidine in relapsed or refractory T-cell acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 trial.

Journal: The Lancet. Haematology

Published: May 19, 2025

Showing 1-12 of 42

Last Updated: 09/26/2026